Vera Therapeutics is a pioneering brand dedicated to revolutionizing the standard of care for patients with immunologic diseases. Their mission is to develop innovative biologic molecules that can effectively treat these conditions. Their lead clinical candidate, atacicept, is a fusion protein that inhibits B cells and plasma cells, which are responsible for producing disease-causing antibodies.

In a Phase 2b clinical trial called ORIGIN, atacicept showed promising results for IgA nephropathy (IgAN), an autoimmune disease that often leads to kidney failure. Vera Therapeutics is now preparing to initiate a Phase 3 clinical trial for Lupus Nephritis (LN), a severe kidney manifestation of systemic lupus erythematosus (SLE). Furthermore, Vera Therapeutics is also advancing MAU868, a monoclonal antibody that neutralizes BK viremia in kidney transplant patients.

With their dedicated team and groundbreaking research, Vera Therapeutics is committed to changing the lives of patients suffering from immunologic diseases